Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment: Public Workshop

December 11, 2020

Docket No. FDA-2020-N-1561 AGENDA

Meeting Webpage

https://www.fda.gov/drugs/news-events-human-drugs/evaluating-effect-opioid-analgesics-riskevaluation-and-mitigation-strategy-education-program

9:00 am	Welcome/Introductions	Judy Staffa, PhD, RPh Associate Director for Public Health Initiatives Office of Surveillance & Epidemiology (OSE) CDER, FDA
9:15 am	Opening Remarks	Patrizia Cavazzoni, MD Center Director (Acting) Deputy Director for Operations Office of the Center Director (OCD), CDER, FDA
9:20 am	Presentations	
	Background on the OA REMS and overview of the day	Claudia Manzo, PharmD Director, Office of Medication Error Prevention and Risk Management, OSE, CDER, FDA
	Blueprint for Heath Care Providers Involved in the Treatment and Monitoring of Patients with Pain: An Overview	LCDR Mark Liberatore, PharmD, RAC Deputy Director for Safety, Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP), Office of Neuroscience (ON), Office of New Drugs (OND), CDER, FDA
	Safer/Competent Opioid Prescribing Education (SCOPE of Pain): Putting the Blueprint into Action	Julie L. White, MS Director, Continuing Medical Education Boston University School of Medicine
	Considerations for studying the impact of the OA REMS on practice behaviors and patient outcomes	Jana McAninch, MD, MPH, MS Senior Medical Epidemiologist Division of Epidemiology, OSE, CDER, FDA
10:20 am	Break	I

Presentations	
A Role of Large Data Sources in Assessing Efforts to Improve Opioid Prescribing	Alec Walker, MD, DrPH Principal World Health Information Science Consultants
Developing and Implementing EHR-based Quality Improvement Opioid Measures	Jan Losby, PhD, MSW Branch Chief, Health Systems and Research Branch, Division of Overdose Prevention, Centers for Disease Control (CDC)
Rethinking study designs to quantify REMS effectiveness	G. Caleb Alexander, MD Professor of Epidemiology and Medicine Johns Hopkins Bloomberg School of Public Health
Opioid Analgesic REMS Assessment plan: Additional indicators of success	Doris Auth, PharmD Deputy Division Director (Acting) Division of Risk Management, OSE, CDER, FDA
Can We Improve Physician Performance and Patient Health Outcomes Through CME/CPD?	Ronald M. Cervero, PhD Professor and Deputy Director Center for Health Professions Education Uniformed Services University of the Health Sciences
Lunch	
Topic 1 Panel discussion: Measurable outcomes to evaluate the effectiveness of Opioid Analgesic REMS training	Moderators: Judy Staffa and Jana McAninch
Topic 2 Panel Discussion: Feasibility of studying the impact of the OA REMS education on prescriber behavior and patient outcomes	Moderators: Judy Staffa and Jana McAninch
Break	
Topic 3 Panel Discussion: Alternative approaches to broadly evaluate the impact of CE on prescriber behaviors and patient outcomes	Moderators: Doris Auth, Claudia Manzo
Pre-registered Public Participation	
High Level Summary	Judy Staffa and Claudia Manzo
Meeting adjourns	
	 A Role of Large Data Sources in Assessing Efforts to Improve Opioid Prescribing Developing and Implementing EHR-based Quality Improvement Opioid Measures Rethinking study designs to quantify REMS effectiveness Opioid Analgesic REMS Assessment plan: Additional indicators of success Can We Improve Physician Performance and Patient Health Outcomes Through CME/CPD? Lunch Topic 1 Panel discussion: Measurable outcomes to evaluate the effectiveness of Opioid Analgesic REMS training Topic 2 Panel Discussion: Feasibility of studying the impact of the OA REMS education on prescriber behavior and patient outcomes Break Topic 3 Panel Discussion: Alternative approaches to broadly evaluate the impact of CE on prescriber behaviors and patient outcomes Pre-registered Public Participation High Level Summary